SLC31A1 and neoplasm: Furthermore, in clinical setting, NSCLC patients with undetectable SLC31A1 expression in their tumors had reduced platinum concentration and tumor response, and lower platinum concentration in clinical specimens correlates directly with reduced tumor response and shorter survival time [9, 10].